Table 1.
Clinical characteristics of patient cohort.
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | |
|---|---|---|---|---|---|
| Age at diagnosis | 7.5 mths | 51 yrs | 18.6 mths | 61 yrs | 73 yrs |
| Sex | Female | Female | Male | Female | Male |
| Event-free survival (days) | 277 | 259 | 228 | 143 | 302 |
| Overall survival (days) | 1464 | 1299 | 370 | 1460 | 431 |
| Drug treatment | NA | Cyta/Ida | NA | Cyta/Ida | Aza/Midostantin |
| Complete Remission end course 1 | CR | CR | CR | No | No |
| Complete Remission end course 2 | CR | CR | CR | CR | No |
| Stem cell transplant | No | No | No | No | No |
| Mutations identified clinically | FLT3, KIT | None | None | None | CEBPA |
| FAB subtype | M4 | M4 | M5 | M4 | M2 |
| Cytogenetics | inv (16) | inv (16) | Normal | t (1;8) | Normal |
| White blood cell count at diagnosis (per mm3) | 45.8 | 196 | 75.1 | 16 | 37 |
| Leukemic blasts at diagnosis (percent) | 62 | 88 | 82 | 80 | 15 |
| LIC at diagnosis (percent) | 0.08 | 0.07 | 0.8 | 0.006 | 0.1 |
| LIC at relapse (percent) | 0.4 | 0.16 | 0.8 | 0.1 | 0.2 |